Literature DB >> 10869771

Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy.

J E Eyles1, E D Williamson, I D Spiers, H O Alpar.   

Abstract

We have compared the ability of intramuscularly and intratracheally administered recombinant F1 and V subunit antigens to safeguard mice from a lethal systemic challenge with plague. The combined subunits (1 microg V plus 5 microg F1) were inoculated either in the 'free' state as a solution, or entrapped within microspheres composed of a biodegradable polyester (Poly-L-lactide), on day 1 and 60 of the experiment. In comparison to the other regimens, introduction of microsphere suspensions into the respiratory tract resulted in statistically elevated levels of specific immunoglobulins in day 82 lung wash samples. A subcutaneous challenge with virulent Yersinia pestis bacteria on day 137, equivalent to more than 10(5) mouse LD(50)s, was comparatively well tolerated by all subunit treatment groups (with survival rates between 66 and 90%). In contrast, 80% of the mice injected intramuscularly with soluble F1 and V were defeated by a 10(7) MLD(50) subcutaneous challenge, whereas the group immunised intramuscularly with microparticles were significantly better protected (p<0.1) with 50% survival. Similarly, mice immunised intratracheally with microparticles were significantly better safeguarded (56% survival) compared with the group immunised with soluble subunits intramuscularly (p<0.01). Soluble sub-units delivered intratracheally afforded 33% protection against 10(7) MLD(50)s. These data indicate that bronchopulmonary administration of microsphere co-encapsulated recombinant F1 and V antigens elicits a similar level of protective immunity against systemic plague infection as that evoked by injecting co-encapsulated subunits into the muscle. Such findings corroborate the thesis that introduction of appropriately formulated F1 and V subunits into the respiratory tract may be an alternative to parenteral immunisation schedules for protecting individuals from plague.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869771     DOI: 10.1016/s0264-410x(00)00128-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.

Authors:  Shixia Wang; Innocent Mboudjeka; Jon D Goguen; Shan Lu
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

2.  Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Authors:  Shixia Wang; Jon D Goguen; Fusheng Li; Shan Lu
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

3.  Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.

Authors:  Helen C Flick-Smith; Jim E Eyles; Richard Hebdon; Emma L Waters; Richard J Beedham; Tony J Stagg; Julie Miller; H Oya Alpar; Les W J Baillie; E Diane Williamson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 4.  Current advances in research and clinical applications of PLGA-based nanotechnology.

Authors:  Jian-Ming Lü; Xinwen Wang; Christian Marin-Muller; Hao Wang; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Expert Rev Mol Diagn       Date:  2009-05       Impact factor: 5.225

5.  Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.

Authors:  Anasuya Chattopadhyay; Steven Park; Guillaume Delmas; Rema Suresh; Svetlana Senina; David S Perlin; John K Rose
Journal:  Vaccine       Date:  2008-10-01       Impact factor: 3.641

6.  Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor.

Authors:  Yoonkyung Do; Arnaud M Didierlaurent; Seongho Ryu; Hyein Koh; Chae Gyu Park; Steven Park; David S Perlin; Bradford S Powell; Ralph M Steinman
Journal:  Vaccine       Date:  2012-09-01       Impact factor: 3.641

7.  Local and systemic immune responses to intratracheal instillation of antigen and DNA vaccines in mice.

Authors:  Catherine Lombry; Aline Marteleur; Mohammed Arras; Dominique Lison; Jamila Louahed; Jean-Christophe Renauld; Véronique Préat; Rita Vanbever
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.580

Review 8.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

Authors:  Malgorzata Smola; Thierry Vandamme; Adam Sokolowski
Journal:  Int J Nanomedicine       Date:  2008

9.  A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.

Authors:  Shixia Wang; Destin Heilman; Fangjun Liu; Theodore Giehl; Swati Joshi; Xiaoyun Huang; Te-hui Chou; Jon Goguen; Shan Lu
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641

10.  Construction of a Live-Attenuated Vaccine Strain of Yersinia pestis EV76-B-SHUΔpla and Evaluation of Its Protection Efficacy in a Mouse Model by Aerosolized Intratracheal Inoculation.

Authors:  Junxia Feng; Yingying Deng; Mengjiao Fu; Xueyuan Hu; Wenbo Luo; Zhiyu Lu; Lupeng Dai; Huiying Yang; Xiaodong Zhao; Zongmin Du; Bohai Wen; Lingxiao Jiang; Dongsheng Zhou; Jun Jiao; Xiaolu Xiong
Journal:  Front Cell Infect Microbiol       Date:  2020-09-08       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.